[1] Fleischmann R. et al. Arthritis Rheumatol. 2018;70 (supp10)

[illegible]

Disclosure of Interests: Roy Fleischmann Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celtrion, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Sanofi-Aventis, UCB, Consultant for: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celtrion, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Sanofi-Aventis, UCB, Jeffrey Enejosa Shareholder of: AbbVie, Inc., Employee of: AbbVie, Inc., In-Ho Song Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, Eduardo Mysler Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Janssen, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medimmune, Pfizer Inc, and Roche, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medimmune, Pfizer Inc, and Roche, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Janssen, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medimmune, Pfizer Inc, and Roche, Louis Besette Grant/research support from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Consultant for: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Speakers bureau: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Charles

- [1] Morisky DE, et al., Predictive Validity of a Medication Adherence Measure for in an Outpatient Setting. *J Clin Hypertens* 2008 May;348-354.
- [2] Krousel-Wood M, et al., New Medication Adherence Scale Versus Pharmacy Fill Rates in Seniors with Hypertension. *Am J Manag Care*. 2009 Jan: 59-66.
- [3] Morisky DE, et al., Improving the Measurement of Self-Reported Medication Nonadherence: Response to Authors. *J Clin Epidemiol* 2011 Mar: 255- 263.
- [4] Morisky Widget™, MMAS™, MMAS4™, MMAS-8™, Morisky Medication Adherence Protocol™, and Morisky Medication Adherence Scale™ is

protected by U.S. and International Trademark and Copyright laws. Permission for use is required. A license agreement is available from: MMAS Research LLC, 14725 NE 20th St., Bellevue WA 98007 or dmorisky@gmail.com.

Acknowledgement: Investigators and patients of APRIIM study

Disclosure of Interests: René-Marc Flipo Consultant for: Honoraria from Novartis as steering committee of this survey, Eric Senbel Consultant for: Nordic Pharma, Speakers bureau: Nordic Pharma, Sonia Tropé: None declared, Elena Zinovieva Employee of: Nordic Pharma, Agnès Courbeyrette Employee of: Nordic Pharma, Hélène Herman-Demars Employee of: Nordic Pharma

DOI: 10.1136/annrheumdis-2019-eular.3171

FRI0149

DISEASE ACTIVITY IN ESCALATION OR DE-ESCALATION OF DOSAGE OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS – THE FIRST RESULTS OF RUSSIAN NATIONAL REGISTER OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB

Inna Gaydukova¹, V Mazurov¹, Elizaveta Vasilenko¹, Evgeniy Zhilyaev², Vyacheslav Poncratov³, Valentina Sorotskaya⁴, Galina Lukina⁵, Oxana Fomina⁶, Aida Babaeva⁷, N Lapkina⁸, Anna Misiyuk⁹, A Pavlova¹⁰, Evgeny Nasonov⁹.
¹North-Western State Medical University, St. Petersburg, Russian Federation;
²European Medical Center, Moscow, Russian Federation; ³Kursk State Medical University, Kursk, Russian Federation; ⁴Tula State Medical University, Tula, Russian Federation; ⁵Moscow Clinical Scientific Center, Moscow, Russian Federation; ⁶Reginal Hospital, Amur, Amur, Russian Federation; ⁷Volgograd State Medical University, Volgograd, Russian Federation; ⁸Yaroslavl State Medical University, Yaroslavl, Russian Federation; ⁹VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; ¹⁰Clinical Hospital Republic of Buryatia, Ulan-Ude, Russian Federation

Background: In previous studies tofacitinib (TF) had demonstrated efficacy of two dosages (10 and 20 mg/day) in patients with rheumatoid arthritis (RA). However, the expected results of switching of TF dosages are unknown.

Objectives: The aim of the study was to evaluate the results of switching of TF dosages in RA patients.

Methods: Were analyzed the data from Russian national register of patients with RA treated with TF (tofacitinib). 415 patients were involved in the register (aug 2018). In statistical analysis were included data from 41 patients with RA (EULAR 2010), who switched dosage of TF at visit 3 and had complete clinical and laboratory data from 5 consecutive visits with an interval of 3 months between the visits. Demographical (age, sex) data, disease activity data DAS28 (Disease activity score), C-reactive protein level were collected, table 1. Changes in disease activity were calculated to patients with switching of the tofa's dosage (the visit before and after the switching).

Results: 1.28 (68%) of patients were treated with NSAIDs, 24 (50%) with 5-10 mg of prednisolone, 34 (82.9) – with methotrexate (10-25 mg/week), biologics – 5 (4.2%).

Table 1. Baseline characteristics of the patients with RA included in the study (n=41)

Parameter	Characteristics
Male, n (%)	10 (24.3)
Caucasians, n (%)	41 (100)
Asians, n (%)	0 (0)
Age of disease onset, years (mean ±SD)	40.1±10.5
Symptoms duration, month (mean ±SD)	98.7± 87.1
Positive rheumatoid factor, n (%)	32 (78)
Positive antibodies to cyclic citrullinated peptide (anti-CCP), n (%)	37 (90.2)
BMI, kg/m ² (mean ±SD)	25.12±5.98
Smokers (current and in the anamnesis), n (%)	33 (80)

From 41 persons with RA 32 patients, who never achieved low disease activity (DAS28<3.2) or remission (DAS28<2.6) elevated the dosage of tofa from 10 to 20 mg/day and 9 patients with DAS28 < 3.2 decreased the dosage from 20 to 10 mg/day.

After escalation of TF dosage DAS28 decreased from 5.42±1.22 to 4.22 ±1.22 (p<0.00), n=32. In 10 patients escalation lead to DAS28-remission (DAS28 <2.6) and in 12 patients - to low disease activity (DAS28<3.2).

10 patients had no clinical or laboratory response on escalation of TF dosage. Interestingly, that responders before escalation of dosage had mean DAS28 3.54 (min 3.2 – max 4.9) and non-responders – 5.54 (min 5.3-max 6.9), p<0.000.

De-escalation of the dosage from 20 to 10 mg/day was not associated with significant changes of DAS28 (1.99 ± 1.25 increased to 2.1 ±0.96 respectively, p=0.82).

Conclusion: Escalation of dosage of TF in RA lead to improvement of the disease activity in non-complete responders, who achieved DAS 28 3.2-5.1, but not in patients with absence of any response (DAS28 before escalation 5.3-6.9). De-escalation of TF dosage in patients with DAS28 < 2.6 dose not lead to significant changes of RA's activity.

REFERENCES:

[1] Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5.

Acknowledgement: Pfizer is sponsor of register Technical support ASTON group

Disclosure of Interests: Inna Gaydukova Grant/research support from: JSC BIOCAD, Speakers bureau: payment from Pfizer, Novartis, Abbvie, Biocad, Selgene, MSD, Sanofi does not exceed 10 000 euros, V Mazurov Grant/research support from: JSC BIOCAD, Elizaveta Vasilenko: None declared, Evgeniy Zhilyaev: None declared, Vyacheslav Poncratov: None declared, Valentina Sorotskaya: None declared, Galina Lukina: None declared, Oxana Fomina: None declared, Aida Babaeva: None declared, N Lapkina: None declared, Anna Misiyuk: None declared, A Pavlova: None declared, Evgeny Nasonov: None declared

DOI: 10.1136/annrheumdis-2019-eular.6265

FRI0150

GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY

Alan Kivitz¹, Daksha Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie A. Di Paolo³, Neelufar Mozaffarian³, Sean Hsueh³, Jiyun Kim³, Wendy Jiang³, Lin Liu³, John Sundry³, Mark C. Genovese⁴. ¹Altoona Center for Clinical Research, Duncansville, United States of America; ²Center for Arthritis and Osteoporosis, Elizabethtown, United States of America; ³Gilead Sciences, Inc., Foster City, United States of America; ⁴Stanford University Medical Center, Palo Alto, United States of America

Background: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK may play an important role in the initiation and progression of autoimmune diseases, including rheumatoid arthritis (RA) and lupus. GS-9876 is a novel, potent, highly selective oral inhibitor of SYK in phase 2 trials for autoimmune diseases.

Objectives: To evaluate the efficacy, safety, and pharmacokinetics of GS-9876, and its impact on biomarkers relevant to RA as well as the SYK and JAK pathways.

Methods: Patients with active RA with prior inadequate response to methotrexate (MTX) or a biologic antirheumatic drug were randomized 1:1:1 to receive GS-9876 30 mg, GS-9876 10 mg, selective JAK1 inhibitor filgotinib (FIL) 200 mg, or matching placebo (PBO) once daily for 12 weeks on a stable background of oral MTX. The primary endpoint for GS-9876 was the change in DAS28(CRP) at week 12. Pharmacokinetics and various biomarkers were evaluated at several time points, including VectraDA and stimulation of whole blood in TruCulture (MyriadRBM) tubes.

Results: A total of 83 patients received the study drug and 79 completed the study. Fourteen patients (16.9%) were male and 69 (83.1%) were female. The majority were white (77, 92.8%). The mean (SD) age at baseline (BL) was 55 (11.5) years (range 18 to 73). The primary and secondary endpoints are reported in Table 1. For DAS28(CRP), the mean (SD) at BL was 5.75 (0.961) with a median of 5.69; a statistically significant reduction at week 12 was observed only in patients receiving FIL as compared to PBO (Table 1). Adverse events (AEs) were reported across all groups (37.5% in the combined GS-9876 arms, 38.1% in FIL, 40.9% in PBO). No deaths or serious AEs were reported. Plasma exposures of all study drugs were comparable to those observed in healthy subjects and historical data. *Ex vivo* stimulated whole blood identified differential responses between GS-9876 and PBO.